ERBB2 and breast cancer: Axillary management in HER2-negative, hormone receptor-positive early breast cancer has shifted toward surgical de-escalation, supported by randomized trials demonstrating that completion ALND can be safely omitted in selected patients with limited nodal involvement, particularly when radiotherapy or genomic risk profiling is integrated.